Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention in Hutchinson-Gilford Progeria

Luciano De Simone1, Serena Chiellino1, Gaia Spaziani1

  • 1Paediatric Cardiology, "Meyer" Children's Hospital, University of Florence, Viale Pieraccini, 24, 50139 Florence, Italy.

Insights

Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic condition. This case report details successful percutaneous coronary intervention for severe coronary artery obstruction in a teen with HGPS.

Area of Science:

  • Cardiology
  • Genetics
  • Pediatrics

Background:

  • Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by LMNA gene mutations, leading to progerin accumulation and premature aging phenotypes, including early cardiovascular disease.
  • Cardiovascular complications, such as atherosclerosis and myocardial infarction, are the primary cause of mortality in HGPS patients, significantly reducing life expectancy.

Observation:

  • A 14-year-old Chinese boy with HGPS presented with precordial pain, tachycardia, and severe hypertension.
  • ECG revealed sinus tachycardia, left ventricular hypertrophy, and ischemic changes. Echocardiography showed preserved left ventricular function with concentric hypertrophy and mitral insufficiency.
  • Elevated high-sensitivity troponin T confirmed Non-ST-Elevation Myocardial Infarction (NSTEMI). Coronary CT angiography identified severe left main coronary artery obstruction.

Findings:

  • Coronary angiography revealed chronic total occlusion of the left main coronary artery and severe stenosis of the right coronary artery.
  • Successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation in the right coronary artery restored left coronary artery perfusion.
  • The patient was initiated on dual antiplatelet therapy and antihypertensive medications.

Implications:

  • This case highlights the feasibility and positive outcomes of urgent PCI in managing acute coronary syndromes in young HGPS patients.
  • Aggressive cardiovascular risk management, including timely revascularization, may improve outcomes and prolong life in individuals with HGPS.
  • Further research into the specific cardiovascular manifestations and optimal management strategies for HGPS is warranted.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
17
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
19
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
233
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
15
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
43